
New resource available view now
Related Posts

IGC Pharma Completes Dosing in Phase 2 CALMA Trial of IGC-AD1 for Agitation in Alzheimer’s Dementia
Final participant completes dosing in 170-participant trial; topline results anticipated during the December 2026/January 2027 timeframe

IGC Pharma Reports Third Quarter 2026 Financial Results and Provides Business Update
CALMA randomized 170 participants; topline results expected following last patient- last dose, database lock and unblinding

POTOMAC, Maryland – October 13, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company advancing Alzheimer’s disease therapeutics and Artificial Intelligence (AI)-enabled healthcare technologies, today

How Sleep Supports Brain Health
Contrary to common belief, sleep is a very active process that keeps our body (and especially our brain) in tip-top shape. It turns out that taking good care of your

IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer’s Trial; Topline Results Expected Q4 2026
POTOMAC, Maryland – September 28, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today announced it has completed enrollment in its CALMA Phase 2 trial evaluating lead